Ironwood Pharmaceuticals, Inc. (IRWD) Stock
Key stats
- Market cap
- $806.23M
- Price / Earnings ratio
- 5.3x
- EPS (TTM)
- $0.91
- Volume
- Loading
- 52-week high
- $5.78
- 52-week low
- $2.40
Source: third-party data provider, as of November 13, 2026
Compare with IRWD
Recent news
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
IRWD
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
IRWD
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
IRWD
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
IRWDNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 76.77
- MACD 12/26/9
- 0.20
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.17
- SMA 50
- $3.95
- Price above SMA 50
- EMA 50
- $3.95
- Price above EMA 50
- SMA 200
- $3.95
- Price above SMA 200
- EMA 200
- $3.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.14 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
IRWDIronwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
IRWDPGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
IRWDIronwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
IRWD
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
IRWD
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
IRWD
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
IRWD
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
IRWD
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
IRWD
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
IRWDNews tone: automated (AI) classification of the article's content, not a price prediction.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas A. McCourt | CEO & Director | 1957 |
| Mr. Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | 1982 |
| Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. | VP & Global Head of Technical Operations | — |
| Mr. John Minardo | Senior VP, Chief Legal Officer & Secretary | 1976 |
| Mr. Jeff Ruberti | Chief Strategy Officer | — |
| Dr. Jeffrey Silber M.D. | Chief Medical Officer, Head of Research & Drug Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 76.77
- MACD 12/26/9
- 0.20
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.17
- SMA 50
- $3.95
- Price above SMA 50
- EMA 50
- $3.95
- Price above EMA 50
- SMA 200
- $3.95
- Price above SMA 200
- EMA 200
- $3.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.0 | +6.6 | ||||||||||
| 2022 | -6.7 | -3.2 | +17.7 | -4.3 | -6.9 | +2.8 | -0.7 | -3.1 | -4.3 | +5.5 | +8.6 | +3.6 |
| 2023 | -6.1 | -1.3 | -7.6 | -2.5 | +2.0 | -2.2 | +6.7 | -21.8 | +4.0 | -2.9 | +9.2 | +11.1 |
| 2024 | +14.3 | -35.4 | -4.0 | -10.0 | -23.4 | -4.3 | +4.8 | -23.2 | -17.3 | -1.7 | -16.0 | +22.4 |
| 2025 | -46.0 | -23.3 | -3.3 | -34.0 | -34.1 | +16.1 | +8.6 | +71.4 | +0.0 | +31.5 | +88.2 | -3.7 |
| 2026 | +14.5 | -30.8 | -1.7 | +5.9 | -19.6 | +21.7 | +2.7 | -3.8 | -7.0 | -6.9 | +40.8 |
